hydroxynefazodone (BioDeep_00000054438)

   

human metabolite Endogenous blood metabolite


代谢物信息卡片


1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-(1-hydroxyethyl)-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one

化学式: C25H32ClN5O3 (485.2194)
中文名称:
谱图信息: 最多检出来源 Mus musculus(blood) 50%

分子结构信息

SMILES: CC(C1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl)O
InChI: InChI=1S/C25H32ClN5O3/c1-20(32)24-27-31(25(33)30(24)17-18-34-23-9-3-2-4-10-23)12-6-11-28-13-15-29(16-14-28)22-8-5-7-21(26)19-22/h2-5,7-10,19-20,32H,6,11-18H2,1H3

描述信息

hydroxynefazodone is a metabolite of nefazodone. Nefazodone (Serzone, Nefadar) is an antidepressant marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries due to the rare incidence of hepatotoxicity (liver damage), which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in every 250,000 to 300,000 patient-years. On June 14, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States and Canada. (Wikipedia)

同义名列表

3 个代谢物同义名

1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-(1-hydroxyethyl)-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one; 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-1,2,4-triazol-3-one; hydroxynefazodone



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yan Mao, Mike-Qingtao Huang, Yuan-Qing Xia, Mohammed Jemal. High-throughput quantitation of nefazodone and its metabolites in human plasma by high flow direct-injection LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2007 Apr; 43(5):1808-19. doi: 10.1016/j.jpba.2006.11.041. [PMID: 17236738]
  • M Jemal, M Huang, Y Mao, D Whigan, M L Powell. Increased throughput in quantitative bioanalysis using parallel-column liquid chromatography with mass spectrometric detection. Rapid communications in mass spectrometry : RCM. 2001; 15(12):994-9. doi: 10.1002/rcm.330. [PMID: 11400209]
  • C Laroudie, D E Salazar, J P Cosson, B Cheuvart, B Istin, J Girault, I Ingrand, J P Decourt. Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects. European journal of clinical pharmacology. 1999 Feb; 54(12):923-8. doi: 10.1007/s002280050576. [PMID: 10192752]
  • A Nacca, G Guiso, C Fracasso, L Cervo, S Caccia. Brain-to-blood partition and in vivo inhibition of 5-hydroxytryptamine reuptake and quipazine-mediated behaviour of nefazodone and its main active metabolites in rodents. British journal of pharmacology. 1998 Dec; 125(7):1617-23. doi: 10.1038/sj.bjp.0702251. [PMID: 9884092]
  • M Yao, V R Shah, W C Shyu, N R Srinivas. Sensitive liquid chromatographic-mass spectrometric assay for the simultaneous quantitation of nefazodone and its metabolites hydroxynefazodone m-chlorophenylpiperazine and triazole-dione in human plasma using single-ion monitoring. Journal of chromatography. B, Biomedical sciences and applications. 1998 Oct; 718(1):77-85. doi: 10.1016/s0378-4347(98)00355-7. [PMID: 9832363]
  • R H Barbhaiya, A B Buch, D S Greene. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. British journal of clinical pharmacology. 1996 Nov; 42(5):573-81. doi: 10.1111/j.1365-2125.1996.tb00112.x. [PMID: 8951188]
  • R H Barbhaiya, U A Shukla, C S Natarajan, D A Behr, D S Greene, S M Sainati. Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis. Clinical pharmacology and therapeutics. 1995 Oct; 58(4):390-8. doi: 10.1016/0009-9236(95)90051-9. [PMID: 7586930]
  • R H Barbhaiya, P H Marathe, D S Greene, R F Mayol, U A Shukla, R R Gammans, K A Pittman, D Robinson. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study. Journal of clinical pharmacology. 1995 Oct; 35(10):974-84. doi: 10.1002/j.1552-4604.1995.tb04013.x. [PMID: 8568015]
  • S Kaul, U A Shukla, R H Barbhaiya. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Journal of clinical pharmacology. 1995 Aug; 35(8):830-9. doi: 10.1002/j.1552-4604.1995.tb04127.x. [PMID: 8522641]
  • R H Barbhaiya, U A Shukla, D S Greene. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. British journal of clinical pharmacology. 1995 Aug; 40(2):161-5. doi: 10.1111/j.1365-2125.1995.tb05771.x. [PMID: 8562300]
  • R H Barbhaiya, U A Shukla, D S Greene. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. European journal of clinical pharmacology. 1995; 49(3):221-8. doi: 10.1007/bf00192383. [PMID: 8665999]
  • R H Barbhaiya, M E Brady, U A Shukla, D S Greene. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. European journal of clinical pharmacology. 1995; 49(3):229-35. doi: 10.1007/bf00192384. [PMID: 8666000]
  • N Ferry, N Bernard, G Cuisinaud, P Rougier, C Trepo, J Sassard. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundamental & clinical pharmacology. 1994; 8(5):463-73. doi: 10.1111/j.1472-8206.1994.tb00827.x. [PMID: 7875642]
  • E BRAUN-MENENDEZ. [Mechanism of renal regression in hypophysectomized rats]. Comptes rendus des seances de la Societe de biologie et de ses filiales. 1950 Sep; 144(17-18):1228-30. doi: NULL. [PMID: 14801905]